Placeholder Banner

BIO letter to FDA on Scientific Challenges and Opportunities to Advance the Development of Individualized Cellular and Gene Therapies

November 17, 2023

BIO submits comments in response to the agency’s request for information (FDA-2023-N-3742)

Download Full Comments Below
FDA-2023-N-3742 RFI Individualized CGT
Discover More
BIO provided general comments and recommended edits Re: FDA-2023-D-3031
BIO joins 30 other national trade associations in speaking out against unprecedented and burdensome FTC-DOJ regulation of mergers
BIO submits specific comments and recommended edits on the draft guidance 2016-D-0643